Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies

FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2

Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug

CellPaleogenomes reveal the evolutionary relationship between modern and cave lions

Endpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cuts

Endpoints NewsSupreme Court sides with Hikma in 'skinny label' case

FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too

Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic

BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2B

FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma

Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times